Patents by Inventor David Rampe
David Rampe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7741493Abstract: The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.Type: GrantFiled: November 29, 2007Date of Patent: June 22, 2010Assignee: Aventis Pharmaceuticals Inc.Inventors: Patrick Shum, Alexandre Gross, Liang Ma, Daniel G. McGarry, Gregory H. Merriman, David Rampe, Garth Ringheim, Jeffrey Stephen Sabol, Francis A. Volz
-
Patent number: 7534803Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: GrantFiled: September 27, 2005Date of Patent: May 19, 2009Assignee: Aventis Pharmaceuticals Inc.Inventors: Craig P. Smith, Michel P. Rathbone, Margaret Petty, David Rampe
-
Patent number: 7326792Abstract: The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.Type: GrantFiled: July 21, 2004Date of Patent: February 5, 2008Assignee: Aventis Pharmaceuticals Inc.Inventors: Patrick Shum, Alexandre Gross, Liang Ma, Daniel G. McGarry, Gregory H. Merriman, David Rampe, Garth Ringheim, Jeffrey Stephen Sabol, Francis A. Volz
-
Patent number: 7230015Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: GrantFiled: March 14, 2005Date of Patent: June 12, 2007Assignee: Aventis Pharmaceuticals Inc.Inventors: Craig P Smith, Michel P Rathbone, Margaret Petty, David Rampe
-
Publication number: 20070129403Abstract: The present invention provides methods of treating schizophrenia and/or glucoregulatory abnormalities in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of formula I wherein in is 0, 1 or 2; n is 0, 1 or 2; p is 0 or 1; each R is independently hydrogen, halogen, trifluoromethyl, C1-C6alkyl, C1-C6alkoxy, benzyloxy, hydroxy, nitro or amino; each R1 is independently hydrogen, C1-C6alkyl, C1-C6alkenyl, C1-C6alkanoyl, halogen, cyano, —C(O)C1-C6alkyl, —C1-C6alkyleneCN, —C1-C6alkyleneNR?R? wherein R? and R? are each independently hydrogen or C1-C6alkyl, —C1-C6alkyleneOC(O)C1-C6alkyl, or —CH(OH)R4 wherein R4 is hydrogen or C1-C6alkyl; R2 is hydrogen, C1-C6alkyl optionally substituted with halogen, hydroxy or benlzyloxy, C1-C6alkenyl, C1-C6alkynyl, —CO2C1-C6alkyl, or —R5—NR?R? wherein R5 is C1-C6alkylene, C1-C6alkenylene or C1-C6alkynylene and R? and R? are each independently hydrogen, C1-C6alkyl or alternatively the group —NR?R? as a wholeType: ApplicationFiled: September 29, 2006Publication date: June 7, 2007Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Craig Smith, David Rampe, Beth Borowsky, Sathapana Kongsamut
-
Patent number: 7179821Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: GrantFiled: March 14, 2005Date of Patent: February 20, 2007Assignee: Aventis Pharmaceuticals Inc.Inventors: Craig P Smith, Michel P Rathbone, Margaret Petty, David Rampe
-
Publication number: 20060025452Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: ApplicationFiled: September 27, 2005Publication date: February 2, 2006Applicant: Avenits Pharmaceuticals Inc.Inventors: Craig Smith, Michel Rathbone, Margaret Petty, David Rampe
-
Patent number: 6967210Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: GrantFiled: February 14, 2002Date of Patent: November 22, 2005Assignee: Aventis Pharmaceuticals Inc.Inventors: Craig P. Smith, Michel P. Rathbone, Margaret Petty, David Rampe
-
Publication number: 20050234105Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: ApplicationFiled: March 14, 2005Publication date: October 20, 2005Applicant: Aventis Pharmaceuticals Inc.Inventors: Craig Smith, Michel Rathbone, Margaret Petty, David Rampe
-
Publication number: 20050159456Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: ApplicationFiled: March 14, 2005Publication date: July 21, 2005Applicant: Aventis Pharmaceuticals Inc.Inventors: Craig Smith, Michel Rathbone, Margaret Petty, David Rampe
-
Publication number: 20050026916Abstract: The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.Type: ApplicationFiled: July 21, 2004Publication date: February 3, 2005Applicant: Aventis Pharmaceuticals Inc.Inventors: Patrick Shum, Alexandre Gross, Liang Ma, Daniel McGarry, Gregory Merriman, David Rampe, Garth Ringheim, Jeffrey Sabol, Francis Volz
-
Publication number: 20040157888Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: ApplicationFiled: February 3, 2004Publication date: August 12, 2004Applicant: Aventis Pharmaceuticals Inc.Inventors: Craig P. Smith, Michel P. Rathbone, Margaret Petty, David Rampe
-
Publication number: 20040157889Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: ApplicationFiled: February 3, 2004Publication date: August 12, 2004Applicant: Aventis Pharmaceuticals Inc.Inventors: Craig P. Smith, Michel P. Rathbone, Margaret Petty, David Rampe
-
Publication number: 20030105150Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: ApplicationFiled: February 14, 2002Publication date: June 5, 2003Inventors: Craig P. Smith, Michel P. Rathbone, Margaret Petty, David Rampe